Abstract
A phase II trial was performed to determine the efficacy and tolerance of docetaxel plus oxaliplatin with hematopoietic growth factor support in previously untreated patients with advanced gastroesophageal adenocarcinoma. Thirty-five patients were entered in this trial. Treatment consisted of 3-weekly docetaxel 80 mg/m2 and oxaliplatin 100 mg/m2 both infused on day 1. A prophylactic 5-day course of human granulocyte colony-stimulating factor 5 microg/kg/day was given subcutaneously, and erythropoietin (10,000 IU subcutaneously three times per week) was administered if hemoglobin was less than 12.0 mg/dl. The confirmed overall response rate was 34%, including two complete responses (6%) and 10 partial responses (28%). Fifteen patients (43%) had stable disease. The median time to response was 2.5 months (1-3.5), the median time to progression was 8.9 (4-42.5) months and the median overall survival time was 11.6 (2.5-51) months. Hematologic toxicity was common, though World Health Organization grade 3 or 4 neutropenia occurred only in six (17%) patients and anemia in six (17%) patients, respectively. Nonhematologic adverse reactions were usually mild-to-moderate. Our data suggest that the combination of docetaxel and oxaliplatin w...Continue Reading
References
Apr 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D KelsenM Brennan
Mar 1, 1995·British Journal of Cancer·S PyrhönenM Kouri
Feb 1, 1996·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M TanakaT Sasaki
Nov 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N W LemmersH J Hoekstra
Jan 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A WebbM Meehan
Jun 1, 1996·Medical Oncology·A I EinzigA B Benson
Feb 1, 1997·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B GlimeliusR Heuman
Feb 18, 1998·World Journal of Surgery·H J KockF W Eigler
Aug 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N BokuI Hyodo
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L PierelliG Scambia
May 16, 2000·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A D RothA Goldhirsch
Jul 15, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·U VanhoeferJ A Wils
Aug 17, 2000·British Journal of Cancer·C KollmannsbergerC Bokemeyer
Aug 24, 2000·American Journal of Clinical Oncology·D MavroudisV Georgoulias
Mar 16, 2001·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K RidwelskiH Lippert
Jun 8, 2001·Seminars in Oncology·T J Littlewood
Dec 4, 2003·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·M EriguchiM Sekiguchi
Dec 6, 2003·Oncology·Birgit SchüllWerner Scheithauer
Feb 18, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Salah-Eddin Al-BatranElke Jaeger
Apr 28, 2005·British Journal of Cancer·F De VitaA R Bianco
Jun 20, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anna D WagnerWolfgang E Fleig
Nov 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric Van CutsemUNKNOWN V325 Study Group
Citations
Mar 25, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B F El-RayesP A Philip
Aug 4, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alicia F C OkinesIan Chau
Aug 5, 2011·Drugs·Jaclyn YoongTrevor Leong